JIB-04, an Inhibitor of Jumonji Histone Demethylase As a Potent Antitubercular Agent Against Mycobacterium Tuberculosis

Overview

Journal Arch Microbiol

Specialty Microbiology

Date 2024 Nov 19

PMID 39560788

Authors

Pei Li

Qiwen Huang

Yanling Xie

Zhu Zhu

Senlin Zhan

Jianzhou Meng

Han Liu

Affiliations

Soon will be listed here.

Abstract

The increasing drug resistance of Mycobacterium tuberculosis (Mtb), coupled with the limited availability of effective anti-tuberculosis medications, poses significant challenges for the management and treatment of tuberculosis (TB). Globally, non-tuberculous mycobacteria (NTM) infections are increasing, with Mycobacterium avium complex and Mycobacterium abscessus (Mab) being the most common in labs and having few treatment options. There's an urgent need for innovative therapies against Mtb and NTM that are effective and have minimal side effects. The study evaluated the in vitro efficacy of JIB-04, a Jumonji histone demethylase inhibitor, against Mtb, Mab, and multidrug-resistant (MDR) clinical isolates using the minimum inhibitory concentration (MIC) assay. We also determined the minimum bactericidal concentrations (MBCs) of JIB-04 against the H37Rv and H37Ra strains. A time-kill assay was performed to assess the comparative efficacy of JIB-04 and rifampicin against H37Ra. Additionally, the study investigated the impact of JIB-04 on biofilm formation and the persistence of H37Ra over extended periods. Our findings demonstrated a substantial inhibitory effect of JIB-04 on the growth of Mab, Mtb, and MDR clinical isolates. JIB-04 showed bactericidal effects at twice the MIC, outperforming rifampicin in reducing viable cell counts over 8 days. It showed moderate cytotoxicity to mammalian cells but effectively inhibited biofilm formation. In our anoxia model, JIB-04 induced a significant, concentration-dependent reduction in bacterial load. JIB-04 is a promising candidate for the treatment of MDR tuberculosis.

References

Abel L, El-Baghdadi J, Bousfiha A, Casanova J, Schurr E . Human genetics of tuberculosis: a long and winding road. Philos Trans R Soc Lond B Biol Sci. 2014; 369(1645):20130428. PMC: 4024222. DOI: 10.1098/rstb.2013.0428. View

Aono A, Chikamatsu K, Yamada H, Kato T, Mitarai S . Association between pncA gene mutations, pyrazinamidase activity, and pyrazinamide susceptibility testing in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2014; 58(8):4928-30. PMC: 4136016. DOI: 10.1128/AAC.02394-14. View

Baird T, Bell S . Cystic Fibrosis-Related Nontuberculous Mycobacterial Pulmonary Disease. Clin Chest Med. 2023; 44(4):847-860. DOI: 10.1016/j.ccm.2023.06.008. View

Benwill J, Wallace Jr R . Mycobacterium abscessus: challenges in diagnosis and treatment. Curr Opin Infect Dis. 2014; 27(6):506-10. DOI: 10.1097/QCO.0000000000000104. View

Berbari E, Hanssen A, Duffy M, Steckelberg J, Osmon D . Prosthetic joint infection due to Mycobacterium tuberculosis: a case series and review of the literature. Am J Orthop (Belle Mead NJ). 1998; 27(3):219-27. View

Chakraborty P, Bajeli S, Kaushal D, Radotra B, Kumar A . Biofilm formation in the lung contributes to virulence and drug tolerance of Mycobacterium tuberculosis. Nat Commun. 2021; 12(1):1606. PMC: 7952908. DOI: 10.1038/s41467-021-21748-6. View

Cowman S, van Ingen J, Griffith D, Loebinger M . Non-tuberculous mycobacterial pulmonary disease. Eur Respir J. 2019; 54(1). DOI: 10.1183/13993003.00250-2019. View

Dalvi M, Wang L, Zhong R, Kollipara R, Park H, Bayo J . Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors. Cell Rep. 2017; 19(8):1669-1684. PMC: 5531293. DOI: 10.1016/j.celrep.2017.04.077. View

de Steenwinkel J, de Knegt G, Ten Kate M, van Belkum A, Verbrugh H, Kremer K . Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis. J Antimicrob Chemother. 2010; 65(12):2582-9. DOI: 10.1093/jac/dkq374. View

10.

Griffith D, Daley C . Treatment of Mycobacterium abscessus Pulmonary Disease. Chest. 2021; 161(1):64-75. DOI: 10.1016/j.chest.2021.07.035. View

11.

Hoffman L, DArgenio D, MacCoss M, Zhang Z, Jones R, Miller S . Aminoglycoside antibiotics induce bacterial biofilm formation. Nature. 2005; 436(7054):1171-5. DOI: 10.1038/nature03912. View

12.

Holla S, Prakhar P, Singh V, Karnam A, Mukherjee T, Mahadik K . MUSASHI-Mediated Expression of JMJD3, a H3K27me3 Demethylase, Is Involved in Foamy Macrophage Generation during Mycobacterial Infection. PLoS Pathog. 2016; 12(8):e1005814. PMC: 4988650. DOI: 10.1371/journal.ppat.1005814. View

13.

Johansen M, Herrmann J, Kremer L . Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus. Nat Rev Microbiol. 2020; 18(7):392-407. DOI: 10.1038/s41579-020-0331-1. View

14.

Jones D, Havlir D . Nontuberculous mycobacteria in the HIV infected patient. Clin Chest Med. 2002; 23(3):665-74. DOI: 10.1016/s0272-5231(02)00015-1. View

15.

Kim M, Cho H, Yoon H, Ahn Y, Park E, Jin Y . JIB-04, A Small Molecule Histone Demethylase Inhibitor, Selectively Targets Colorectal Cancer Stem Cells by Inhibiting the Wnt/β-Catenin Signaling Pathway. Sci Rep. 2018; 8(1):6611. PMC: 5919936. DOI: 10.1038/s41598-018-24903-0. View

16.

So S, Park Y, Kang S, Han J, Sunwoo J, Lee W . Therapeutic Potency of Induced Pluripotent Stem-Cell-Derived Corneal Endothelial-like Cells for Corneal Endothelial Dysfunction. Int J Mol Sci. 2023; 24(1). PMC: 9821383. DOI: 10.3390/ijms24010701. View

17.

Li Y, Ding L, Zhang Y, Zhou B, Man G, Wang M . Histone demethylase Kdm5c regulates osteogenesis and bone formation via PI3K/Akt/HIF1α and Wnt/β-catenin signaling pathways. Genes Dis. 2023; 11(1):64-66. PMC: 10425781. DOI: 10.1016/j.gendis.2023.02.041. View

18.

Martin A, Camacho M, Portaels F, Palomino J . Resazurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs: rapid, simple, and inexpensive method. Antimicrob Agents Chemother. 2003; 47(11):3616-9. PMC: 253784. DOI: 10.1128/AAC.47.11.3616-3619.2003. View

19.

Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H . OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 2006; 3(11):e466. PMC: 1664607. DOI: 10.1371/journal.pmed.0030466. View

20.

Matteelli A, Carvalho A, Dooley K, Kritski A . TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol. 2010; 5(6):849-58. PMC: 2921705. DOI: 10.2217/fmb.10.50. View